Alexo Therapeutics is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types.
December 9, 2017 – Alexo Therapeutics Presents Preclinical Data Demonstrating that ALX148 Bridges Innate and Adaptive Immunity to Enhance Antitumor Immune Response at the 59th Annual ASH Meeting
November 13, 2017 – Alexo Therapeutics to Present ALX148 Preclinical Data at the 59th American Society of Hematology Annual Meeting (ASH)
November 10, 2017 – Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma